Skip to main content
. 2011 May 16;108(22):9060–9065. doi: 10.1073/pnas.1100387108

Fig. 4.

Fig. 4.

ARX201-induced increase in IGF-1 standard deviation scores (SDS) in GH-deficient human clinical trial subjects. ARX201 (starting dose 0.02 and 0.06 mg/kg) was administered weekly by subcutaneous injection for up to 26 weeks, and induced an IGF-1 SDS increase into the normal range within one day.